Documents behind the reading
Every source has a scope.
A label describes its named medicine. A trial reports results in its enrolled population. A provider page documents an advertised program. These records cannot be substituted for one another.
Provider product and mechanism claims · Checked 2026-09-27
CoreAge Rx: Tirzepatide Microdosing Therapy
Read the original document ↗Articles citing this record
Provider offer; direct public HTML supplements extraction · Checked 2026-09-27
CoreAge Rx: Shared microdose GLP-1 offer and terms
Read the original document ↗Articles citing this record
Exact approved-product labeling · Checked 2026-09-27
Zepbound prescribing information, revised August 2026
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing review: what follows from two receptors?
- Tirzepatide microdosing care comparison: match the offer to the evidence
- Ivím tirzepatide microdosing review: broader benefits need specific evidence
- Noom tirzepatide Microdose Plus review: identify the program before reading the results
- Tirzepatide and two receptors: what does the mechanism establish?
- Tirzepatide sleep-apnea evidence: where the approved use begins and ends
- Tirzepatide, biomarkers and healthspan: which outcome was actually measured?
- Tirzepatide versus semaglutide: why the trial is not a microdosing winner list
Exact approved-product labeling · Checked 2026-09-27
Mounjaro prescribing information, revised August 2026
Read the original document ↗Articles citing this record
Current regulatory safety information · Checked 2026-09-27
FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing review: what follows from two receptors?
- Tirzepatide microdosing care comparison: match the offer to the evidence
- Ivím tirzepatide microdosing review: broader benefits need specific evidence
- Noom tirzepatide Microdose Plus review: identify the program before reading the results
- Tirzepatide versus semaglutide: why the trial is not a microdosing winner list
Regulatory explanation · Checked 2026-09-27
FDA: Compounding and the FDA, Questions and Answers
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing review: what follows from two receptors?
- Tirzepatide microdosing care comparison: match the offer to the evidence
- Ivím tirzepatide microdosing review: broader benefits need specific evidence
- Noom tirzepatide Microdose Plus review: identify the program before reading the results
Provider tirzepatide program identification and access limits · Checked 2026-09-27
Noom: Microdose GLP-1Rx Plus Program
Read the original document ↗Articles citing this record
Provider marketing, care description and offer qualifications · Checked 2026-09-27
Noom: Microdose GLP-1Rx shared offer
Read the original document ↗Articles citing this record
Provider program-specific pricing explanation · Checked 2026-09-27
Noom: How much does Noom cost in 2026, updated September 22, 2026
Read the original document ↗Articles citing this record
Provider catalog and reported-outcome qualifications · Checked 2026-09-27
Noom: Medication programs and pricing directory
Read the original document ↗Articles citing this record
Provider product, service and pricing claims · Checked 2026-09-27
Ivím Health: GLP-1 Microdosing
Read the original document ↗Articles citing this record
Provider contractual service description; not an individual legal assessment · Checked 2026-09-27
Ivím Health: Terms and Conditions, effective May 27, 2026
Read the original document ↗Articles citing this record
Regulatory explanation · Checked 2026-09-27
FDA: Understanding the Risks of Compounded Drugs
Read the original document ↗Articles citing this record
Primary randomized trials, full text · Checked 2026-09-27
Malhotra and colleagues: SURMOUNT-OSA primary trial report, NEJM 2024
Read the original document ↗Articles citing this record
Historical approval announcement · Checked 2026-09-27
FDA: First medication approval for obstructive sleep apnea, December 2024
Read the original document ↗Articles citing this record
Regulatory evidence definitions · Checked 2026-09-27
FDA Facts: Biomarkers and Surrogate Endpoints
Read the original document ↗Articles citing this record
Primary randomized trial follow-up, full text · Checked 2026-09-27
Jastreboff and colleagues: Tirzepatide for Obesity Treatment and Diabetes Prevention, 2024
Read the original document ↗Articles citing this record
Primary randomized comparative trial, full text · Checked 2026-09-27
Aronne and colleagues: SURMOUNT-5 tirzepatide versus semaglutide trial, NEJM 2025
Read the original document ↗Articles citing this record
Current exact approved-product labeling · Checked 2026-09-27
Novo Nordisk: Wegovy prescribing information, revised June 2026
Read the original document ↗Articles citing this record
Official mixed-product offer; eligibility, semaglutide trial attribution, older-intervention footnote and compensated-testimonial limits. No individual prescription or tirzepatide microdose verified. · Checked 2026-09-29
Hims — weight-care offer and evidence footnotes
Read the original document ↗Articles citing this record
Official state availability, clinical assessment and semaglutide evidence descriptions. Company summaries do not constitute independent review of the underlying studies. · Checked 2026-09-29
Hims — weight-care FAQ
Read the original document ↗Articles citing this record
Official approved-product indications and selected pharmacology. The adult high-risk type 2 diabetes cardiovascular indication is not general longevity evidence or approval of an oral compound. · Checked 2026-09-29
Eli Lilly and Company — Mounjaro prescribing information, August 2026
Read the original document ↗Articles citing this record
Official approved-product indications, warning and selected clinical-pharmacology context. Adult weight and OSA populations remain specific; this does not validate compounds, arbitrary microdoses or personal use. · Checked 2026-09-29
Eli Lilly and Company — Zepbound prescribing information, August 2026
Read the original document ↗Articles citing this record
- Hims tirzepatide review: which medicine produced the advertised result?
- Ro tirzepatide review: manufacturer trials and member surveys answer different questions
- Calibrate tirzepatide review: when published program averages disagree
- PlushCare tirzepatide review: a clinical consultation is not a new efficacy study
- LifeMD tirzepatide review: a personalized estimate is not an observed outcome
- Henry Meds tirzepatide review: an oral offer with semaglutide evidence
Official named-product service and evidence qualifications. Manufacturer findings and mixed-medication member survey remain distinct; personal predictions and outcomes are unverified. · Checked 2026-09-29
Ro — weight-care offer, trial qualifications and survey
Read the original document ↗Articles citing this record
Primary open-label randomized 72-week comparison in adults without type 2 diabetes. Weight/waist endpoints and Lilly roles remain explicit; no online-service ranking or universal clinical superiority follows. · Checked 2026-09-29
Aronne and colleagues — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Read the original document ↗Articles citing this record
Official named-brand clinical service, drug-trial attributions, observational Points comparison and qualified insurance arrangements. Program association is not randomized evidence or personal eligibility. · Checked 2026-09-29
WeightWatchers Clinic — tirzepatide offer and evidence
Read the original document ↗Articles citing this record
Primary SURMOUNT-1 prediabetes follow-up with 176-week treatment and 17-week off-treatment context. Population, attrition and Lilly roles limit transfer to other products or permanent-prevention claims. · Checked 2026-09-29
Jastreboff and colleagues — Tirzepatide for Obesity Treatment and Diabetes Prevention
Read the original document ↗Articles citing this record
Primary randomized 52-week OSA trials in adults with obesity; PAP groups, endpoints and Lilly funding/roles retained. Not a provider program, microdose, PAP-withdrawal or long-term survival study. · Checked 2026-09-29
Malhotra and colleagues — Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Read the original document ↗Articles citing this record
Official broad catalog and selected member-result description. Branded and compounded tirzepatide references do not identify the ingredient of every Found program. · Checked 2026-09-29
Found — clinical weight-care offer
Read the original document ↗Articles citing this record
Official dedicated offer names semaglutide and includes nonapproval qualifications. Its preventive language is not direct evidence for a tirzepatide microdose or the advertised compound. · Checked 2026-09-29
Found — compounded semaglutide microdose offer
Read the original document ↗Articles citing this record
Official explanatory article dated October 27, 2025. Its semaglutide pilot description and broader benefit statements remain attributed; the underlying pilot was not independently assessed. · Checked 2026-09-29
Found — When Less is More: How Microdosing GLP-1s Can Personalize Your Weight Care Journey
Read the original document ↗Articles citing this record
Primary explanation of off-label use of approved drugs. This differs from a never-approved compounded product and is not an endorsement of an individual use. · Checked 2026-09-29
FDA — Understanding Unapproved Use of Approved Drugs
Read the original document ↗Articles citing this record
Primary regulatory information on unapproved GLP-1 products and compounding. Adverse-event reports are not incidence estimates or provider-specific causal findings. · Checked 2026-09-29
FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Read the original document ↗Articles citing this record
Official tirzepatide examples, assessment and no-compounding policy. Reported averages and tolerability summaries differ from the FAQ; underlying Results Report analysis is unverified. · Checked 2026-09-29
Calibrate — medication approach and results
Read the original document ↗Articles citing this record
Official combined clinical, coaching and learning program. Published outcomes and broad health statements remain company claims; longer-term figures differ from the FAQ. · Checked 2026-09-29
Calibrate — Metabolic Reset program overview
Read the original document ↗Articles citing this record
Official eligibility, clinical visit and program-result descriptions. Employer-specific requirements and differing outcome summaries remain separate and unresolved. · Checked 2026-09-29
Calibrate — program FAQ
Read the original document ↗Articles citing this record
Official team and program claims. Weight outcome spans pathways with and without medicine; A1c observation concerns the highest starting readings, not all patients or isolated tirzepatide use. · Checked 2026-09-29
Form Health — care model and outcomes
Read the original document ↗Articles citing this record
Primary regulatory explanation distinguishing biological indicators, validated surrogates and clinical outcomes. Validation and benefit-risk interpretation depend on context. · Checked 2026-09-29
FDA — Biomarkers and Surrogate Endpoints
Read the original document ↗Articles citing this record
Official approved-medication policy, Zepbound example and existing-primary-care requirements. Examples do not establish a complete current formulary or personal treatment. · Checked 2026-09-29
Form Health — eligibility, records and medication FAQ
Read the original document ↗Articles citing this record
Official conditional assessment, named Zepbound/Mounjaro consultations and prior-obesity-record exception. Early-result marketing does not identify a PlushCare tirzepatide outcome trial. · Checked 2026-09-29
PlushCare — clinical weight-management service
Read the original document ↗Articles citing this record
Official conditional service, branded-study estimate and varied-medication testimonials. Government and government-related primary or secondary coverage exclusions apply; personal forecast accuracy is unverified. · Checked 2026-09-29
LifeMD — clinical weight-care offer and qualifications
Read the original document ↗Articles citing this record
Official oral offer includes semaglutide assessment wording and an injected-semaglutide cohort result. These mismatches remain unresolved; neither establishes efficacy of the oral preparation. · Checked 2026-09-29
Henry Meds — compounded oral tirzepatide offer
Read the original document ↗Articles citing this record
Primary explanation of compounding, approval, generic distinctions and oversight. No particular compounder, batch or supplied medicine is verified by this general guidance. · Checked 2026-09-29
FDA — Understanding the Risks of Compounded Drugs
Read the original document ↗Articles citing this record
Official clinical weight-care description with separate compounded tirzepatide and Zepbound entries. Provider discretion, new-customer membership qualifications and separate medication costs remain; no selected individual product or microdose protocol verified. · Checked 2026-09-29
Mochi Health: weight care and tirzepatide options
Read the original document ↗Articles citing this record
Official assessment, Mounjaro/Zepbound examples and GIP/GLP-1 explanation. These statements do not identify a personal preparation or measure Mochi-specific clinical outcomes. · Checked 2026-09-29
Mochi Health: medicine examples and receptor explanation
Read the original document ↗Articles citing this record
Standalone FDA finished-product terminology distinguishes the preparation from its ingredient. It does not approve an unseen product, verify supply or select treatment. · Checked 2026-09-29
FDA: finished drug product definition
Read the original document ↗Articles citing this record
- Mochi Health tirzepatide evidence: the medicine listing changes the question
- Eden tirzepatide evidence: the contract, member report and drug study describe different things
- Amazon One Medical tirzepatide evidence: broad weight care does not identify a medicine
- DrHouse tirzepatide evidence: the named medicine examples need their own labels
Current approved-product label with adult weight/obesity-related OSA scope and distinct nonclinical and human pharmacology contexts. It does not establish provider supply, compounded-form equivalence, a microdose indication or individual suitability. · Checked 2026-09-29
Zepbound prescribing information, revised August 2026
Read the original document ↗Articles citing this record
- Mochi Health tirzepatide evidence: the medicine listing changes the question
- Lavender Sky Health tirzepatide evidence: named forms need matching studies
- RemedyMeds tirzepatide evidence: member reports are different from a drug trial
- Amble tirzepatide evidence: a compound description is not an approval record
- Eden tirzepatide evidence: the contract, member report and drug study describe different things
- Fridays tirzepatide evidence: what does the advertised success rate count?
- Sesame tirzepatide evidence: a named medicine and the advertised milestones use different records
- Amazon One Medical tirzepatide evidence: broad weight care does not identify a medicine
- DrHouse tirzepatide evidence: the named medicine examples need their own labels
Current product-specific glycemic indications and cardiovascular-event risk reduction in high-risk adults with type 2 diabetes. This is not a blanket preventive, longevity or compounded-product claim. · Checked 2026-09-29
Mounjaro prescribing information, revised August 2026
Read the original document ↗Articles citing this record
- Mochi Health tirzepatide evidence: the medicine listing changes the question
- Amble tirzepatide evidence: a compound description is not an approval record
- Sesame tirzepatide evidence: a named medicine and the advertised milestones use different records
- DrHouse tirzepatide evidence: the named medicine examples need their own labels
FDA explanation distinguishes compounds from approved generics and describes federal/state oversight. Lack of premarket approval is not absence of regulation; no individual pharmacy or legal-eligibility audit is claimed. · Checked 2026-09-29
FDA: compounded medicines, generics and oversight
Read the original document ↗Articles citing this record
- Mochi Health tirzepatide evidence: the medicine listing changes the question
- Lavender Sky Health tirzepatide evidence: named forms need matching studies
- RemedyMeds tirzepatide evidence: member reports are different from a drug trial
- Amble tirzepatide evidence: a compound description is not an approval record
- Eden tirzepatide evidence: the contract, member report and drug study describe different things
- Fridays tirzepatide evidence: what does the advertised success rate count?
Selected terms distinguishing professional clinical relationships and platform services. No individual agreement, clinical quality or uninterrupted care verified. · Checked 2026-09-29
Mochi Health: professional service relationships
Read the original document ↗Articles citing this record
Official conditional branded and compounded plan descriptions. Broad prevention and regulation claims are critically qualified; the branded monthly fee excludes medicine and differs from the FAQ’s billing description. No chosen product or personal access verified. · Checked 2026-09-29
Lavender Sky Health: GLP-1 plans and named Zepbound option
Read the original document ↗Articles citing this record
Official receptor and comparative-weight discussion, plus compounded oral/sublingual semaglutide and tirzepatide descriptions. These do not establish equivalent exposure, outcomes or individual availability across forms; the primary trial supplies separate design and population limits. · Checked 2026-09-29
Lavender Sky Health: mechanism, comparison and compounded-form descriptions
Read the original document ↗Articles citing this record
Eli Lilly-sponsored randomized, open-label 72-week study in adults with obesity or qualifying overweight without diabetes. Defined treatments, weight endpoint, sponsor role and attrition remain attached; no provider ranking, universal tolerability or compounded-microdose equivalence is established. · Checked 2026-09-29
SURMOUNT-5: tirzepatide compared with semaglutide, May 2025
Read the original document ↗Articles citing this record
- Lavender Sky Health tirzepatide evidence: named forms need matching studies
- RemedyMeds tirzepatide evidence: member reports are different from a drug trial
- Fridays tirzepatide evidence: what does the advertised success rate count?
- Sesame tirzepatide evidence: a named medicine and the advertised milestones use different records
Official state/pharmacy and e-consult qualifications, remote-care limits, consultation fees and no-subscription wording. These remain distinct from the branded monthly-plan description; no individual eligibility or contract interpretation is established. · Checked 2026-09-29
Lavender Sky Health: access, consultation fees and care limits
Read the original document ↗Articles citing this record
Official compounded semaglutide/tirzepatide offer with pathway claims, mixed self-reported member results and quality-test claims. A separate microdose block does not by proximity identify tirzepatide; no independent outcome or pharmacy audit is claimed. · Checked 2026-09-29
RemedyMeds: named compounds and reported program results
Read the original document ↗Articles citing this record
Selected clinical/platform, payment-without-shipment and warranty provisions. The twelve-month warranty excludes branded medication and any microdosing period; a contractual remedy is not clinical efficacy evidence. · Checked 2026-09-29
RemedyMeds: professional entities, paid access and warranty exclusions
Read the original document ↗Articles citing this record
FDA distinguishes an unapproved use of an approved drug from the approval status of the finished medicine. This does not confer approval on a compound or supply personal treatment advice. · Checked 2026-09-29
FDA: unapproved uses of approved drugs
Read the original document ↗Articles citing this record
Official clinician-directed weight-care offer and conditional compounded tirzepatide description. Receptor language and promotional imagery do not establish an approved generic, selected preparation, clinical equivalence or personal eligibility. · Checked 2026-09-29
Amble: clinical weight care and compounded tirzepatide
Read the original document ↗Articles citing this record
Selected remote-care limitations and payment terms. Platform nonparticipation and possible provider participation are distinct; no universal Medicare exclusion or individual coverage guarantee is inferred. · Checked 2026-09-29
Amble: telehealth and federal-program distinctions
Read the original document ↗Articles citing this record
Eli Lilly-sponsored randomized follow-up of participants with prediabetes and obesity or qualifying overweight through 176 weeks and 17 weeks off treatment. Attrition and off-treatment changes remain; no permanent protection or healthy-person lifespan claim is established. · Checked 2026-09-29
SURMOUNT-1: obesity treatment and diabetes-prevention follow-up
Read the original document ↗Articles citing this record
Official online consultation and weight-care offer. Mixed self-reported member results and a separate Wegovy research statement do not isolate tirzepatide effects. No current individual preparation, product supply or visual presentation is verified. · Checked 2026-09-29
Eden: independent clinical care and distinct outcome statements
Read the original document ↗Articles citing this record
Selected guarantee language names compounded tirzepatide only if available and prescribed, excludes specified forms and limits approved refunds to eligible first-six-month membership fees. Cash-pay reimbursement restrictions are not treated as blanket beneficiary exclusion. · Checked 2026-09-29
Eden: conditional tirzepatide guarantee and financial limits
Read the original document ↗Articles citing this record
FDA distinguishes biological measurements, clinical endpoints and context-dependent surrogate validation. The framework does not interpret a personal test or establish a provider’s outcomes. · Checked 2026-09-29
FDA: biomarkers and surrogate endpoints
Read the original document ↗Articles citing this record
- Eden tirzepatide evidence: the contract, member report and drug study describe different things
- Fridays tirzepatide evidence: what does the advertised success rate count?
- Amazon One Medical tirzepatide evidence: broad weight care does not identify a medicine
- DrHouse tirzepatide evidence: the named medicine examples need their own labels
Official branded/compounded tirzepatide and separate Zepbound entries with receptor and tolerability marketing. Multiple plan descriptions do not establish a selected formulation, personal price or comparative clinical outcome. · Checked 2026-09-29
Fridays: named tirzepatide options and comparative claims
Read the original document ↗Articles citing this record
Selected clinical/platform and subscription provisions. Missing the 72-hour cancellation cutoff renews the next cycle, with cancellation effective at that next cycle’s end; no prescription or clinical result is guaranteed. · Checked 2026-09-29
Fridays: clinical practices and renewal conditions
Read the original document ↗Articles citing this record
Official dedicated microdose page names compounded semaglutide and Daily Oral/Daily Nasal labels. Its success statistic concerns fulfillment and delivery, not clinical efficacy; registration is distinct from finished-product approval. · Checked 2026-09-29
Fridays: semaglutide microdose identity and delivery statistic
Read the original document ↗Articles citing this record
Official weight-care and billing information. Zepbound is named, but the advertised milestones cite semaglutide research; medication cost and stated Quest laboratory exclusions remain separate from clinical outcomes. · Checked 2026-09-29
Sesame: Success weight care, Zepbound and milestone qualifications
Read the original document ↗Articles citing this record
Selected terms require certification that the user is not a federal healthcare-program beneficiary, including Medicare, Medicaid or TRICARE. This is an access restriction, not merely a refusal to bill insurance. · Checked 2026-09-29
Sesame: federal healthcare-program beneficiary exclusion
Read the original document ↗Articles citing this record
Official individualized primary-care weight assessment, support and conditional prescriptions/referrals. The reviewed page does not name tirzepatide or establish a microdosing offer, selected product or medicine-specific outcome. · Checked 2026-09-29
Amazon One Medical: primary-care weight management
Read the original document ↗Articles citing this record
Official recurring membership and separately billed office/video care distinctions, including possible visits for long-term medicines. No personal coverage, refill or encounter outcome is guaranteed. · Checked 2026-09-29
Amazon One Medical: membership and scheduled encounters
Read the original document ↗Articles citing this record
Official general access and separately described Seniors practice with plan/location qualifications. Restrictions from another Amazon service are not imported into this primary-care review. · Checked 2026-09-29
Amazon One Medical: Seniors and insurance participation
Read the original document ↗Articles citing this record
Official named medicine examples subject to physician assessment, possible laboratory testing and clinical discretion. Product-specific indications come from the separate current labels; no selected medicine or microdose protocol is verified. · Checked 2026-09-29
DrHouse: conditional Zepbound and Mounjaro examples
Read the original document ↗Articles citing this record
Official virtual physician weight-care description with qualified delivery and evidence-based results language. Visit access is not a medication bundle, universal supply promise or controlled study of DrHouse patient outcomes. · Checked 2026-09-29
DrHouse: weight-care service and outcome language
Read the original document ↗Articles citing this record
Official physician-visit pricing and plan-specific insurance information, including Medicare examples and Medicaid exclusion. These do not establish personal coverage or an included medicine supply. · Checked 2026-09-29
DrHouse: visit coverage and medication-cost distinctions
Read the original document ↗Articles citing this record
Selected policy distinguishes no care from completed care, guidance or referrals and lists specific medication-request and refill-history exclusions. It does not establish a universal refund rule for every GLP-1 prescribing decision; no individual refund determination is made. · Checked 2026-09-29
DrHouse: clinical care and visit-refund boundaries
Read the original document ↗Articles citing this record
Official medical weight-management service describing clinical examination, tests, individual planning and possible approved obesity medicines. The service does not establish a selected tirzepatide product, microdosing offer or measured institutional longevity result. · Checked 2026-09-29
Get Medical Weight Management Care | Cleveland Clinic
Read the original document ↗Articles citing this record
Official nonsurgical Obesity and Medical Weight Loss Center description. A personalized multidisciplinary plan is a service statement, not a controlled trial of one medicine or proof of an individual outcome. · Checked 2026-09-29
Obesity and Medical Weight Loss Center | Cleveland Clinic
Read the original document ↗Articles citing this record
Official general obesity-care access information. Referral is usually unnecessary, while insurer requirements and medical-need prioritization remain; these general conditions do not extend Jacksonville-specific services to every Mayo campus. · Checked 2026-09-29
Obesity - Care at Mayo Clinic - Mayo Clinic
Read the original document ↗Articles citing this record
Official first-visit description for the Bariatric Center in Jacksonville. Zepbound is one possible prescription example; individual product selection, access and outcomes remain unverified. It is not a confirmed microdosing offer. · Checked 2026-09-29
Bariatric Center in Jacksonville - Your first appointment
Read the original document ↗Articles citing this record
Official medical weight-loss service covering clinical history, habits, behavior and nutrition assessment. Multicomponent care is not a tirzepatide trial, a verified personal prescription or a measured comparison with another institution. · Checked 2026-09-29
Medical Weight Loss
Read the original document ↗Articles citing this record
Official Duke Lifestyle and Weight Management Center account of consultation and continuing management. The description establishes clinical support without establishing a particular preparation, pharmacy or individual treatment result. · Checked 2026-09-29
Duke Lifestyle and Weight Management Center
Read the original document ↗Articles citing this record
Official adult Complex Weight Management Clinic within the Center for Lifestyle Medicine. Risk-factor reduction and healthier habits are program aims; they are not quantified tirzepatide outcomes or a shared workflow across all Northwestern programs. · Checked 2026-09-29
The Northwestern Medicine Complex Weight Management Clinic
Read the original document ↗Articles citing this record
Official Western Suburbs Bariatric Surgery and Metabolic Health nonsurgical service. Physician and dietitian assessment, follow-up and conditional medicines retain this program scope; no exact tirzepatide product is established. · Checked 2026-09-29
Nonsurgical Weight Loss Services in the Western Suburbs
Read the original document ↗Articles citing this record
Official Medical Weight Management Program account of clinical nutrition, measurements and physician/dietitian assessment. Medication review does not confirm GLP-1 prescribing. The program’s stated literature support is attributed to UCLA and is not independently evaluated here as a nutrition trial. · Checked 2026-09-29
Medical Weight Management Program Overview
Read the original document ↗Articles citing this record
Official nutrition maintenance program describing individual dietitian support and group classes. This does not establish a prescribing or refill service, selected medicine or controlled treatment outcome. · Checked 2026-09-29
Weight Maintenance Program
Read the original document ↗Articles citing this record
Official medically supervised weight-loss service describing comprehensive evaluation and possible lifestyle, medicine and behavioral support. Its GLP-1 category does not identify an individual finished product or demonstrate a healthspan outcome. · Checked 2026-09-29
Medical Weight Loss Treatment
Read the original document ↗Articles citing this record
Official Weight Management Program description of medicines, including GLP-1s, when appropriate. Conditional class-level prescribing is not confirmation of an exact tirzepatide product, pharmacy, microdosing offer or personal eligibility. · Checked 2026-09-29
Weight Management Program
Read the original document ↗Articles citing this record
Official medical and surgical Weight Management Program across New York City and Long Island, with nonsurgical prescribing expertise. Broad institutional claims do not supply product-specific outcome data or guarantee individual access. · Checked 2026-09-29
Weight Management Program
Read the original document ↗Articles citing this record
Official medication-treatment page naming Zepbound, Wegovy and Saxenda and describing ongoing supervision. The examples do not establish a complete current formulary or personal prescription; exact tirzepatide receptor and indication language comes from the separately cited current label. · Checked 2026-09-29
Medication for Obesity
Read the original document ↗Articles citing this record
Official Metabolic Health and Weight Loss Program description of tailored nonsurgical goals and medically supervised options. A health-oriented mission is not a demonstrated longevity result or a confirmed tirzepatide microdosing service. · Checked 2026-09-29
Metabolic Health & Weight Loss Program | Yale Medicine
Read the original document ↗Articles citing this record
Official multidisciplinary Center for Weight Management description. Its proposed 2022 relocation remains historical wording rather than confirmation of current locations or access. Program breadth does not identify an individual medicine. · Checked 2026-09-29
Center for Weight Management | Yale Medicine
Read the original document ↗Articles citing this record
Official Weight Management page available through an indexed copy viewed September 29, 2026, reporting a same-day crawl after direct access was unavailable. Direct-origin freshness and individual access remain unconfirmed. Physician evaluation and conditional medication management do not establish a particular product or trial outcome. · Checked 2026-09-29
Johns Hopkins Medicine — Weight Management
Read the original document ↗Articles citing this record
Official Healthful Eating, Activity & Weight Program page available through an indexed copy viewed September 29, 2026, reporting a same-day crawl. Current direct-origin availability is unconfirmed. Initial in-person and possible later video or clinic visits are qualified service descriptions, not a verified remote-only pathway or tirzepatide offer. · Checked 2026-09-29
Johns Hopkins Medicine — Healthful Eating, Activity & Weight Program
Read the original document ↗Articles citing this record
Official Lifestyle Medicine FAQ with an outdated Belviq example, interpreted alongside FDA’s February 2020 withdrawal communication. The public list is not a verified current medicine catalogue or evidence of what a clinician presently prescribes. · Checked 2026-09-29
Center for Lifestyle Medicine Frequently Asked Questions
Read the original document ↗Articles citing this record
FDA definitions separating active ingredient, dosage form and finished drug product. These definitions do not authenticate or approve an unspecified preparation, establish availability or select treatment for a person. · Checked 2026-09-29
Drugs@FDA Glossary of Terms
Read the original document ↗Articles citing this record
- Cleveland Clinic weight-care evidence: what can an assessment measure?
- Mayo Clinic weight-care evidence: a Zepbound example is more specific than a drug-class heading
- Johns Hopkins weight-care evidence: which population supports the proposed benefit?
- UCLA weight-care evidence: body measurements do not establish a tirzepatide offer
- Stanford weight-care evidence: how far does a GLP-1 category take the claim?
- NYU Langone weight-care evidence: named medicines make the comparison more precise
FDA explanation distinguishing compounded preparations from approved generic medicines. It does not verify any institution’s practice, pharmacy, exact product or individual legal eligibility. · Checked 2026-09-29
Compounding and the FDA: Q & A
Read the original document ↗Articles citing this record
FDA February 13, 2020 lorcaserin withdrawal communication, recording its safety-based request and the manufacturer’s agreement to stop marketing. This qualifies an old institutional medicine example; it does not establish current prescribing at Northwestern. · Checked 2026-09-29
FDA requests withdrawal of Belviq, Belviq XR
Read the original document ↗Articles citing this record
FDA Zepbound prescribing information revised August 2026. Product indications and pharmacology distinguish adult weight/obesity-related OSA scope, nonclinical observations and stated human study context. They do not confirm institutional supply or an individual treatment decision. · Checked 2026-09-29
Zepbound prescribing information, revised August 2026
Read the original document ↗Articles citing this record
- Cleveland Clinic weight-care evidence: what can an assessment measure?
- Mayo Clinic weight-care evidence: a Zepbound example is more specific than a drug-class heading
- Duke Health weight-care evidence: a multidisciplinary program is not a drug comparison trial
- Northwestern weight-care evidence: an old medicine list cannot define today’s options
- Stanford weight-care evidence: how far does a GLP-1 category take the claim?
- NYU Langone weight-care evidence: named medicines make the comparison more precise
- Yale Medicine weight-care evidence: health goals need a defined outcome
FDA Mounjaro prescribing information revised August 2026. Its type 2 diabetes glycemic scope and cardiovascular-event risk reduction in high-risk adults with type 2 diabetes remain product- and population-specific; they are not blanket longevity or compounded-product claims. · Checked 2026-09-29
Mounjaro prescribing information, revised August 2026
Read the original document ↗Articles citing this record
- Mayo Clinic weight-care evidence: a Zepbound example is more specific than a drug-class heading
- Johns Hopkins weight-care evidence: which population supports the proposed benefit?
- Northwestern weight-care evidence: an old medicine list cannot define today’s options
- Stanford weight-care evidence: how far does a GLP-1 category take the claim?
- NYU Langone weight-care evidence: named medicines make the comparison more precise
- Yale Medicine weight-care evidence: health goals need a defined outcome
FDA explanation of biomarkers, clinical endpoints and surrogate endpoints, including limits even for validated surrogates. A general evidence framework does not interpret a personal measurement or establish institutional results. · Checked 2026-09-29
FDA Facts: Biomarkers and Surrogate Endpoints
Read the original document ↗Articles citing this record
- Cleveland Clinic weight-care evidence: what can an assessment measure?
- Northwestern weight-care evidence: an old medicine list cannot define today’s options
- UCLA weight-care evidence: body measurements do not establish a tirzepatide offer
- Stanford weight-care evidence: how far does a GLP-1 category take the claim?
- Yale Medicine weight-care evidence: health goals need a defined outcome
Eli Lilly-sponsored randomized, double-blind, placebo-controlled 52-week trials in adults with obesity and moderate-to-severe OSA, excluding diabetes. PAP and non-PAP populations, attrition and stated limits remain; results are not personal treatment directions or long-term cardiovascular/PAP-adherence evidence. · Checked 2026-09-29
Malhotra and colleagues — SURMOUNT-OSA primary report, 2024
Read the original document ↗Articles citing this record
Eli Lilly-sponsored SURMOUNT-1 follow-up of participants with prediabetes and obesity or qualifying overweight, through 176 weeks and 17 weeks off treatment. Disease-progression findings retain attrition and off-treatment limits; no general lifespan or institution-specific outcome is established. · Checked 2026-09-29
Jastreboff and colleagues — Tirzepatide for Obesity Treatment and Diabetes Prevention, first published November 2024
Read the original document ↗Articles citing this record
Eli Lilly-sponsored randomized, open-label 72-week tirzepatide–semaglutide comparison in adults with obesity or qualifying overweight without diabetes. Weight outcomes, sponsor role and attrition remain explicit. Author affiliation is not proof that the affiliated nutrition program supplies the studied medicine; no microdosing or institution-ranking inference. · Checked 2026-09-29
Aronne and colleagues — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, May 2025
Read the original document ↗Articles citing this record
Provider primary source · Checked 2026-10-04
SuperHealthy Rx: official microtirz offer
Read the original document ↗Articles citing this record
Provider product and mechanism claims · Checked 2026-10-04
Likeness Rx — GLP-1 weight care
Read the original document ↗Articles citing this record
Provider service information · Checked 2026-10-10
CoreAge Rx: advertised shipping and support
Read the original document ↗Articles citing this record
Provider service information · Checked 2026-10-10
SuperHealthy Rx: advertised shipping and support
Read the original document ↗Articles citing this record
Payment-plan eligibility · Checked 2026-10-10
Affirm: eligibility and payment-plan terms
Read the original document ↗Articles citing this record
Federal expense-eligibility guidance · Checked 2026-10-10
IRS: eligible medical expenses for HSA and FSA payments
Read the original document ↗Articles citing this record
Rendered provider offer and claims · Checked 2026-10-15
Healis: Microdosing offer with tirzepatide selected
Read the original document ↗Articles citing this record
Rendered provider service description · Checked 2026-10-15
Healis: services, provider roles and pharmacy partners
Read the original document ↗Articles citing this record
Rendered provider billing policy · Checked 2026-10-15
Healis: Cancellation and Refund Policy
Read the original document ↗Articles citing this record
Regulatory guidance · Checked 2026-10-15